Canaccord Genuity initiated coverage on WAVE Life Sciences (NASDAQ:WVE) with a Buy rating on Monday, citing the company’s robust pipeline of RNA-based medicines.
The research firm highlighted several key assets in Wave’s portfolio, including WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD), which has imminent 200mg multidose data expected in the third quarter of 2024, followed by higher 400mg single dose data later in the fall.
Canaccord also pointed to WVE-007 for obesity, with initial clinical data anticipated in the fourth quarter of 2025, as a significant market opportunity for the company.
The firm noted that Wave is approaching a potential first commercial approval with WVE-N531 for Duchenne Muscular Dystrophy (DMD) Exon 53 within the next year, representing a near-term catalyst.
Additionally, Canaccord mentioned Wave’s Huntington disease program, WVE-003, which is expected to enter a potentially registrational Phase 2/3 study following IND filing in the second half of 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.